TrialThe Lancet. Oncology2016

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

Stephanie M de Boer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.